Salvador D R K, Rey N R, Ramos G C, Punzalan F E R
Section of Cardiology, Department of Medicine, Philipine General Hospital, Taft Avenue, Ermita, Manila, Philippines.
Cochrane Database Syst Rev. 2004(1):CD003178. doi: 10.1002/14651858.CD003178.pub2.
Loop diuretics, when given as intermittent bolus injections in acutely decompensated heart failure, may cause fluctuations in intravascular volume, increased toxicity and development of tolerance. Continuous infusion has been proposed to avoid these complications and result in greater diuresis, hopefully leading to faster symptom resolution, decrease in morbidity and possibly, mortality.
To compare the effects and adverse effects of continuous intravenous infusion of loop diuretics with those of bolus intravenous administration among patients with congestive heart failure Class III-IV.
We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2003), MEDLINE (1966 to 2003), EMBASE (1980 to 2003) and the HERDIN database. We also contacted pharmaceutical companies.
Randomized controlled trials comparing the efficacy of continuous intravenous infusion versus bolus intravenous administration of loop diuretics in congestive heart failure were included
Two reviewers independently assessed study eligibility, methodological quality and did data extraction. Included studies were assessed for validity. Authors were contacted when feasible. Adverse effects information was collected from the trials.
Eight trials involving 254 patients were included. In seven studies which reported on urine output, the output (as measured in cc/24 hours) was noted to be greater in patients given continuous infusion with a weighted mean difference (WMD) of 271 cc/24 hour (95%CI 93.1 to 449; p<0.01). Electrolyte disturbances (hypokalemia, hypomagnesemia) were not significantly different in the two treatment groups with a relative risk (RR) of 1.47 (95%CI 0.52 to 4.15; p=0.5). Less adverse effects (tinnitus and hearing loss) were noted when continuous infusion was given, RR 0.06 (95%CI 0.01 to 0.44; p=0.005). Based on a single study, the duration of hospital stay was significantly shortened by 3.1days with continuous infusion WMD -3.1 (95%CI -4.06 to -2.20; p<0.0001) while cardiac mortality was not significantly different in the two treatment groups, RR 0.47 (95% CI 0.33 to 0.69; p<0.0001). Based on two studies, all cause mortality was not significantly different in the two treatment groups, RR 0.52 (95%CI 0.38 to 0.71; p<0.0001).
REVIEWER'S CONCLUSIONS: Currently available data are insufficient to confidently assess the merits of the two methods of giving intravenous diuretics. Based on small and relatively heterogenous studies, this review showed greater diuresis and a better safety profile when loop diuretics were given as continuous infusion. The existing data still does not allow definitive recommendations for clinical practice and larger studies should be done to more adequately settle this issue.
在急性失代偿性心力衰竭患者中,静脉推注襻利尿剂可能会导致血管内容量波动、毒性增加以及耐受性的产生。有人提出持续静脉输注可避免这些并发症,并能产生更大的利尿作用,有望更快地缓解症状,降低发病率,甚至可能降低死亡率。
比较持续性静脉输注襻利尿剂与静脉推注襻利尿剂对Ⅲ-Ⅳ级充血性心力衰竭患者的疗效和不良反应。
我们检索了Cochrane对照试验中心注册库(2003年第2期《Cochrane图书馆》)、MEDLINE(1966年至2003年)、EMBASE(1980年至2003年)以及HERDIN数据库。我们还联系了制药公司。
纳入比较持续性静脉输注与静脉推注襻利尿剂治疗充血性心力衰竭疗效的随机对照试验。
两名评价者独立评估研究的入选资格、方法学质量并进行数据提取。对纳入的研究进行有效性评估。可行时与作者进行联系。从试验中收集不良反应信息。
纳入了8项涉及254例患者的试验。在7项报告尿量的研究中,持续性静脉输注组患者的尿量(以cc/24小时为单位测量)更多,加权平均差(WMD)为271 cc/24小时(95%CI 93.1至449;p<0.01)。两个治疗组的电解质紊乱(低钾血症、低镁血症)无显著差异,相对危险度(RR)为1.47(95%CI 0.52至4.15;p=0.5)。持续性静脉输注时观察到的不良反应(耳鸣和听力丧失)较少,RR为0.06(95%CI 0.01至0.44;p=0.005)。基于一项研究,持续性静脉输注使住院时间显著缩短3.1天,WMD为-3.1(95%CI -4.06至-2.20;p<0.0001);而两个治疗组的心脏死亡率无显著差异,RR为0.47(95%CI 0.33至0.69;p<0.0001)。基于两项研究,两个治疗组的全因死亡率无显著差异,RR为0.52(95%CI 0.38至0.71;p<0.0001)。
目前可得的数据不足以可靠地评估这两种静脉给予利尿剂方法的优缺点。基于规模较小且相对异质性的研究,本综述显示持续性静脉输注襻利尿剂时利尿作用更强且安全性更好。现有数据仍无法为临床实践提供明确建议,应开展更大规模的研究以更充分地解决这一问题。